Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

被引：2
|
作者：
Rodriguez, Cesar [1 ]
Weisel, Katja [2 ]
Baz, Rachid C. [3 ]
Polepally, Akshanth R. [4 ]
Ross, Jeremy A. [4 ]
Jin, Ziyi [4 ]
D'Amico, Kristin [4 ]
Bueno, Orlando F. [4 ]
Fleming, Leanne Lash [4 ]
Voorhees, Peter M. [5 ]
机构：
[1] Wake Forest Univ Sch Med, Med Oncol & Hematol, Winston Salem, NC USA
[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[4] AbbVie Inc, N Chicago, IL USA
[5] Atrium Hlth Wake Forest Baptist, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Plasma Cell Disorders Sect, Charlotte, NC USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157977
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7326 / 7327
页数：2
相关论文
共 50 条
  • [31] A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Gonsalves, Wilson, I
    Neparidze, Natalia
    Allred, Jacob B.
    Kumar, Shaji K.
    Reid, Joel M.
    Shapiro, Geoffrey
    Costello, Brian A.
    Piekarz, Richard
    Baz, Rachid C.
    Devarakonda, Srinivas
    BLOOD, 2022, 140 : 7315 - 7316
  • [32] Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Nooka, Ajay K.
    O'Donnell, Elizabeth K.
    Weller, Edie A.
    Couture, Nicole R.
    Wallace, Ellen E.
    Burke, Jill N.
    Harrington, Cynthia C.
    Puccio-Pick, Marie
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Raje, Noopur S.
    BLOOD, 2015, 126 (23)
  • [33] Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
    Gonsalves, Wilson I.
    Devarakonda, Srinivas
    Baz, Rachid
    Neparidze, Natalia
    Adjei, Alex A.
    Kunos, Charles
    Kumar, Shaji K.
    BLOOD, 2019, 134
  • [34] Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma.
    Caravita, T
    Siniscalchi, A
    Niscola, P
    Santinelli, S
    Buccisano, F
    Montanaro, M
    De Fabritiis, P
    Amadori, S
    BLOOD, 2003, 102 (11) : 382B - 383B
  • [35] A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs
    Dejardin, David
    Lesaffre, Emmanuel
    Hamberg, Paul
    Verweij, Jaap
    PHARMACEUTICAL STATISTICS, 2014, 13 (03) : 196 - 207
  • [36] A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
    Hansson, Markus
    Gimsing, Peter
    Badros, Ashraf
    Niskanen, Titti Martinsson
    Nahi, Hareth
    Offner, Fritz
    Salomo, Morten
    Sonesson, Elisabeth
    Mau-Sorensen, Morten
    Stenberg, Yvonne
    Sundberg, Annika
    Teige, Ingrid
    Van Droogenbroeck, Jan
    Wichert, Stina
    Zangari, Maurizio
    Frendeus, Bjorn
    Korsgren, Magnus
    Poelman, Martine
    Tricot, Guido
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2730 - 2736
  • [37] An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
    Kropff, Martin
    Kienast, Joachim
    Bisping, Guido
    Berdel, Wolfgang E.
    Gaschler-Markefski, Birgit
    Stopfer, Peter
    Stefanic, Martin
    Munzert, Gerd
    ANTICANCER RESEARCH, 2009, 29 (10) : 4233 - 4238
  • [38] A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort
    Berdeja, Jesus G.
    Gregory, Tara K.
    Faber, Edward A.
    Hart, Lowell L.
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Flinn, Ian W.
    Matous, Jeffrey V.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (04) : 428 - 435
  • [39] CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
    Scheyi, Stephen
    Morgan, Gareth J.
    Ramasamy, Karthik
    Hazel, Beth
    Phekoo, Karen
    Corderoy, Sophie
    Jenner, Matthew
    Davies, Faith
    BLOOD, 2008, 112 (11) : 1270 - 1271
  • [40] A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
    Berenson, James R.
    Klein, Leonard
    Rifkin, Robert M.
    Patel, Priti
    Dixon, Sandra
    Ou, Ying
    Cartmell, Alan
    BLOOD, 2013, 122 (21)
12345